Viyash Scientific Limited’s Board of Directors met on August 11, 2026, approving the unaudited financial results for the quarter ended June 30, 2026. Key decisions included the allotment of 10,30,775 equity shares under its ESOP Scheme 2026 and the approval of a Rights Issue subscription to its wholly-owned subsidiary, Alivira Animal Health Limited, for up to ₹400.02 crore. These actions are expected to increase the company’s paid-up share capital and strengthen the subsidiary’s financial structure.
Board Approves Key Strategic Decisions
Viyash Scientific Limited (formerly Sequent Scientific Limited) announced key outcomes from its Board of Directors meeting held on August 11, 2026. The Board reviewed and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the independent auditor’s limited review report.
Employee Stock Option Scheme Allotment
A significant decision was the approval for the allotment of 10,30,775 equity shares of face value ₹2 each, fully paid. These shares are issued at an exercise price of ₹101 per equity share, including a premium of ₹99 per share, under the Viyash Scientific Limited Employee Stock Option Scheme, 2026 (“ESOP Scheme 2026”). This allotment will increase the company’s issued and paid-up equity share capital from ₹87,77,53,626 (43,88,76,813 shares) to ₹87,98,15,176 (43,99,07,588 shares).
Subsidiary Investment Approved
Further, the Board approved the subscription to equity shares of Alivira Animal Health Limited (“AAHL”), a wholly-owned subsidiary, through a Rights Issue. The overall consideration for this subscription is up to ₹400,02,15,648 (Rupees Four Hundred Crore Two Lakh Fifteen Thousand Six Hundred and Forty-Eight Only). This investment is intended to strengthen AAHL’s capital structure and reduce interest burden, with the subscription amount being adjusted against intercompany loans.
Subsidiary Incorporation in Vietnam
The Board also approved the incorporation of a step-down subsidiary in Vietnam through AAHL or its Irish subsidiary. This new entity is expected to focus on the importation, registration, marketing, sale, and distribution of animal health products and active pharmaceutical ingredients in Vietnam.
Financial Highlights for Q1 FY27
The unaudited standalone financial results for the quarter ended June 30, 2026, show a profit after tax of ₹209.20 million. For the consolidated results, the profit after tax for the same period was ₹792.90 million.
Source: BSE
